CVS Pharmacy Pays $600,000 To Settle Controlled Substances Act Allegations
Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
      • Fee Waiver
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Recibir Actualizaciones
  • Scam Alert
  • Menú Completo
  • English
  • Español

Main Menu

Explore DEA
  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
    • DEA Museum
    • Wall of Honor
    • Contáctenos
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas

Sobrescribir enlaces de ayuda a la navegación

  • Inicio
  • CVS Pharmacy Pays $600,000 To Settle Controlled Substances Act Allegations

CVS Pharmacy Pays $600,000 To Settle Controlled Substances Act Allegations

Octubre 20, 2016
|
Share Article
|
Download Press Release
For Immediate Release
Contact: Kristen Govostes
Phone Number: (617) 557-2100

OCT 20 - HARTFORD, Conn. - Michael J. Ferguson Special Agent in Charge of the Drug Enforcement Administration for New England and Deirdre M. Daly, United States Attorney for the District of Connecticut, announced that CVS Pharmacy, Inc. (CVS) has agreed to pay the federal government a total of $600,000 to resolve alleged violations of civil provisions of the Controlled Substances Act at stores in Southington and New Britain.

The government alleges that, on at least 2,886 occasions, the CVS store located at 326 Main Street in Southington failed to keep paper Schedule III-V prescriptions either in a separate prescription file or readily retrievable location away from other prescription records in violation of the law.  In addition, on 31 occasions, the store failed to keep Schedule III-V purchase invoices in a readily accessible location separate and apart from other records required to be kept under law.

The government further alleges that, on at least 4,936 occasions, the CVS store located at 713 Main Street in New Britain failed to keep paper Schedule III-V prescriptions either in a separate prescription file or readily retrievable location away from other prescription records in violation of the law.  In addition, on six occasions, the store failed to keep Schedule III-V purchase invoices in a readily accessible location separate and apart from other records required to be kept under law.

Congress, with the passage of the Controlled Substances Act, took steps to attempt to create “a closed system” of distribution for controlled substances in which every facet of the handling of the substances, from their manufacture to their consumption by the ultimate user, was to be subject to intense governmental regulation.  This mission was taken against the backdrop of trying to prevent the diversion and abuse of legitimate controlled substances while at the same time ensuring an adequate supply of those substances needed to meet the medical and scientific needs of the United States.  Accurate record keeping at retail pharmacies helps ensure that investigators can keep track of how many controlled substances a pharmacy should have and does have on hand.

As part of the settlement agreement, CVS has agreed that certain pharmacy supervisors, district managers, regional managers and loss prevention managers will attend a training session where the U.S. Attorney’s Office and Drug Enforcement Administration will provide information concerning federal regulatory obligations related to controlled substances.  CVS will share that information to all active pharmacists and pharmacy technicians, and will continue to provide recurring controlled substances training to its pharmacy staff.

This matter was investigated by the Drug Enforcement Administration’s Office of Diversion Control in Rocky Hill and the Connecticut Department of Consumer Protection, Drug Control Division, and was prosecuted by Assistant U.S. Attorney Alan M. Soloway.

Download Press Release
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

Jarod Forget Special Agent in Charge - New England
@DEANewEngland
  • Facebook
  • X
  • Email
  • Quienes Somos
    • Sobre
    • Contáctenos
    • Museo DEA
  • Recursos
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000
Contact the Webmaster